Results 91 to 100 of about 36,320 (224)

Prostacyclin and EDHF

open access: yes, 2000
In response to various neurohumoral substances endothelial cells release nitric oxide (NO), prostacyclin and produce hyperpolarization of the underlying vascular smooth muscle cells by a yet unknown mechanism attributed to an endothelium-derived ...
Félétou, M, Vanhoutte, PM
core  

Prostacyclin in liver disease: a potential therapeutic option.

open access: yes, 2007
Complex molecular and cellular mechanismsare involved in t progression of hepatic fibrosis. Recent studies have show stellate cells, endothelin, cytokines and prostacyclin play cru pathology.
ZARDI EM   +3 more
core   +1 more source

Comparative effects of nitroglycerin and nitroprusside on prostacyclin generation in adult human vessel wall [PDF]

open access: yes, 1983
The precise mechanism of vasodilatory actions of nitroso-compounds is not clear. It has been suggested that these drugs might modulate release of the vasodilator, prostacyclin, from cultured endothelial cells and bovine arteries or potentiate actions of ...
Faro, Richard   +5 more
core   +1 more source

BCP crystals increase prostacyclin production and upregulate the prostacyclin receptor in OA synovial fibroblasts: potential effects on mPGES1 and MMP-13 [PDF]

open access: yes, 2007
SummaryObjectiveTo investigate the potential involvement of prostacyclin in basic calcium phosphate (BCP) crystal-induced responses in osteoarthritic synovial fibroblasts (OASF).MethodsOASF grown in culture were stimulated with BCP crystals. Prostacyclin
McCarthy, G.M.   +4 more
core   +1 more source

Double-blind controlled trial of prostacyclin in cerebral infarction.

open access: yes, 1985
Thirty-two patients with acute cerebral infarction received either prostacyclin or placebo intermittently for 65 hours. Pulse and blood pressure were not altered by prostacyclin. After infusion there was no change in infarct volume or cerebral blood flow
N Lewtas   +7 more
core   +1 more source

A Case of IgG4‐Related Disease Developing During Long‐Term High‐Dose Intravenous Epoprostenol Therapy in a Patient With Idiopathic Pulmonary Arterial Hypertension

open access: yesPulmonary Circulation
Long‐term intravenous (IV) epoprostenol is a key therapy for pulmonary arterial hypertension (PAH); however, rare immune‐mediated conditions occurring during therapy remain incompletely characterised.
Takashi Inao   +9 more
doaj   +1 more source

PHARMACOLOGICAL PROPERTIES OF MM-706, A NEW PROSTACYCLIN DERIVATIVE

open access: yes, 1995
. 1. In human platelet-rich plasma, platelet aggregation induced in vitro by collagen (10 μg/ml) or thrombin (50 mU/ml) was dose-dependently inhibited by increasing concentrations of prostacyclin or of the new derivative (±)(5E)-13,14-didehydro-ω ...
LILLE U   +5 more
core   +1 more source

Role of phosphoinositides in the regulation of endothelial prostacyclin production.

open access: yes, 1988
To elucidate the role of the phosphoinositide signal transduction system in endothelial endothelial prostacyclin production, endothelial cells from human umbilical veins previously labelled with 3H-inositol were incubated with thrombin or histamine ...
H Halldórsson, M Kjeld, G Thorgeirsson
core   +1 more source

DDAVP stimulates prostacyclin production

open access: yes, 1982
Des-amino-D-arginine vasopressin (DDAVP) stimulates the release of factor VIII and plasminogen activator from the vascular endothelium. An infusion of exogenous factor VIII given to haemophiliacs causes an increase in platelet activation. This activation
Lowe, G. D.   +7 more
core   +2 more sources

Home - About - Disclaimer - Privacy